Targeting & Treating Cancer
Progenics is committed to improving patient care through the detection, treatment, and management of cancer. Prospective patients or their physicians who may be interested in participating in these clinical trials may wish to refer to information on these pages or contact the clinical department at 844-643-5710.
Clinical trials often involve patients with specific health conditions who benefit from receiving medication and treatment that would not otherwise be available to them. These trials provide information on the benefits, side effects and possible uses for new drugs or expanded uses for existing medications. Results from clinical trials are submitted for review to the U.S. Food and Drug Administration (FDA) and other regulatory authorities elsewhere, which determine safety and efficacy standards for medical products. If a medicine meets these standards, it can be approved and becomes available by prescription.
The National Institutes of Health offers up-to-date information on clinical trials, including ours, at www.clinicaltrials.gov.
Information on all clinical trials involving products being developed by Progenics is posted here.
- AZEDRA (Ultra-Orphan Radiotherapeutic)
- AZEDRA Expanded Access Program
- 1404 (PSMA Targeted SPECT/CT Imaging Agent)
- PyL (PSMA Targeted PET Imaging Agent)
- 1095 (PSMA Targeted Small Molecule Therapeutic)
For more information on the products in our clinical trials, click here.